Holen Sie sich die Stockscreener-App
11.08
1.37%
0.15
Handel nachbörslich:
11.08
Schlusskurs vom Vortag:
$10.93
Offen:
$10.96
24-Stunden-Volumen:
3.95M
Relative Volume:
0.86
Marktkapitalisierung:
$987.71M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-4.278
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
+0.54%
1M Leistung:
+0.18%
6M Leistung:
+42.05%
1J Leistung:
+54.32%
1-Tages-Spanne:
$10.91
$11.09
1-Wochen-Bereich:
$10.90
$11.09
52-Wochen-Spanne:
$2.8647
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
11.08 | 984.22M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
| 2022-08-25 | Hochstufung | Stifel | Hold → Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-07-12 | Eingeleitet | Guggenheim | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-12 | Eingeleitet | Jefferies | Buy |
| 2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN
Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex
Is Verve Therapeutics Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com
(VERV) Trading Advice - news.stocktradersdaily.com
What analysts say about Verve Therapeutics Inc. stockExceptional trading performance - jammulinksnews.com
Verve Therapeutics Inc. Stock Analysis and ForecastGame-changing capital returns - Autocar Professional
3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa
Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks
Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN
Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BMO Capital Downgrades Verve Therapeutics to Market Perform, $13.50 Price Target - MarketScreener
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):